This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 1999;282:1805.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Encouraged by preliminary findings that an antilymphoma vaccine has a clear antitumor effect, the National Cancer Institute (NCI) is planning a large phase 3 clinical trial of the experimental vaccine. The vaccine, which is derived from a patient's own cancer cells, is intended to prevent recurrences of the disease.

The study, published in the October Nature Medicine, involved 20 patients with follicular lymphoma who had achieved a complete clinical response after chemotherapy. The patients were then given a vaccine formulated with tumor-associated antigens (from their own tumor cells) and granulocyte-monocyte colony-stimulating factor (used as an immune adjuvant).

Follicular lymphoma is a malignancy that is associated with a specific chromosomal translocation, and tumor cells with this translocation often persist in the circulation of patients who are in complete clinical remission. Those who have this molecular marker of residual disease appear to be at increased of relapse.

Molecular . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?